Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision to give control to dialysis users through more flexible and accessible dialysis care, announced today the formation of a North American Medical Advisory Board (MAB). This group of highly esteemed kidney care thought leaders will provide clinical expertise and guidance as Quanta brings its portable hemodialysis system SC+ to the United States market to enable greater flexibility in the delivery of life sustaining dialysis care.

The Medical Advisory Board consists of prominent nephrologists and is chaired by Dr. Paul Komenda, Chief Medical Officer (CMO) at Quanta. Bringing to bear extensive clinical and academic research, Dr. Komenda is a fellow of both the American Society of Nephrology and the Royal College of Physicians and Surgeons, Canada. Additionally, Dr. Komenda has authored and published over 160 peer-reviewed articles focusing on health services research, home dialysis and clinical nephrology.

Members of Quanta’s North American Medical Advisory Board include:

• Dr. Christos Argyropoulos, MD: Dr. Christos Argyropoulos is the division chief of nephrology at the University of New Mexico Health Sciences Center. He currently conducts research on kidney related biomarkers, middle molecule removal by dialysis platforms and big data. Dr. Argyropoulos’ clinical interests focus on outreach nephrology, home dialysis and diabetic kidney disease. Dr. Argyropoulos trained in internal medicine at the University of Cincinnati and in nephrology and transplant nephrology at the University of Pittsburgh Medical Center.
• Dr. Christopher Chan, MD, FRCPC: Dr. Chan is the divisional director of nephrology, professor of medicine, and holds the R Fraser Elliott Chair in Home Dialysis at the Toronto General Hospital, University Health Network in Canada. He is also the deputy physician in chief of economics at the University Health Network. He serves as associate editor for the Clinical Journal of the American Society of Nephrology. Dr. Chan joined the division of nephrology at Toronto General Hospital, University Health Network in 2002, after completing post-graduate training in internal medicine and nephrology at the University of Toronto. He has contributed over 200 peer-reviewed articles and has written extensively on home dialysis.
• Dr. Shaminder Gupta, MD: Dr. Gupta has been a practicing nephrologist in Louisiana for 17 years where he focuses on the long-term management of chronic kidney disease and end-stage renal disease. He has a special interest in population health and has SM-00146-A served as the state lead for hypertension and chronic kidney disease in Louisiana. He is currently the associate chief medical officer of Monogram Health, a kidney disease benefit management and care delivery company, and chief medical officer of Monogram Kidney Care Clinic, an in-home and virtual kidney clinic that provides leading care in 20 states. He previously served as president of the National Kidney Foundation of Louisiana and founded its home dialysis task force.
• Dr. Andrew E. Lazar, MD: Dr. Lazar is the chief of nephrology at Ahuja Medical Center in Ohio. In addition, he is medical director for Natera where he works to promote the use of genetic testing for kidney disease patients. He is also medical director at both Dialyze Direct and Renew Dialysis. He is the founder of Peloton Medical Devices, a medical engineering company focused on the development of a dialysis safety device. He also founded Cleveland Kidney Disease Associates and Affiliated Dialysis of Ohio, which is now owned and operated by Dialyze Direct. Affiliated Dialysis of Ohio was the first provider of home dialysis therapies in nursing home facilities for the state of Ohio. Dr. Lazar also started Cleveland Home Dialysis, one of the largest providers of home hemodialysis and peritoneal dialysis in Northeast Ohio.
• Dr. Bijal V. Patel, MD: Dr. Patel is the director of home therapies for Balboa Nephrology Medical Group (BNMG), chief of nephrology for Sharp Rees-Stealy and physician home champion for Fresenius Kidney Care. He previously served as medical advisor for Cricket Health. Through the practice of medicine, Dr. Patel strives to give patients the best opportunity to live well with kidney disease. By overcoming barriers, educating patients, and addressing social determinants of health, he achieves high rates of home modalities and living donor transplantation. Dr. Patel currently serves as chairman of the board for BNMG and was named San Diego’s top doctor in the field of nephrology by San Diego Magazine in 2020.
• Dr. Brigitte Schiller, MD: Dr. Schiller is CMO at Satellite Healthcare where she has been responsible for quality, physician leadership, and research and development since 2010. As CMO, Dr. Schiller leads efforts for the delivery of care to more than 8,000 dialysis patients with more than 20% of these patients undergoing home dialysis. She also serves as chief of staff and directs Satellite Healthcare’s clinical research efforts. Dr. Schiller has participated as investigator in multiple United States Food & Drug Administration (FDA) trials and is a published author in many areas of end-stage renal disease care, including home dialysis. She serves on the expert panel for the United States Renal Data System database.

The launch of Quanta’s North American Medical Advisory Board comes on the heels of the Company’s $245 million Series D funding round announced earlier this summer. This funding will accelerate Quanta’s global operational development and United States commercial roll-out, strongly positioning the company to pursue a $12 billion-dollar total addressable market opportunity in the United States alone.

SAVE THE DATE

Quanta Dialysis Technologies, a British medical technology innovator, kindly invites you to save the date for a Webinar on Monday 21 September 2020 at 16:00 BST | 11.00am ET | 08.00am PT.

The virtual presentation will feature expert speakers covering a range of topics with a focus on home dialysis and end with a live moderated Q&A, led by Tina Tan, Executive Editor at FirstWord Medtech, where you will have the opportunity to address questions to the panel.

Current featured speakers

John E. Milad, Chief Executive Officer, Quanta Dialysis Technologies
Veronika Dubajova, European Medtech Analyst, Goldman Sachs
Dr Sandip Mitra, Consultant Nephrologist, Manchester University NHS Foundation Trust
Dr Paul Komenda, Chief Medical Officer, Quanta Dialysis Technologies
Maddy Warren, Patient Advocate and Home Dialysis Patient

If you would like more information, please contact quanta@consilium-comms.com or to attend, please click here to register.

About Quanta Dialysis Technologies – quantadt.com About Quanta and SC+ Based in the Midlands of the UK, Quanta is a technology-enabled provider of innovative dialysis products and services. Quanta aims to improve the lives of dialysis patients through beautifully engineered solutions. The lead product SC+ is a small, simple and versatile
haemodialysis system designed to provide greater freedom and flexibility in the delivery of life sustaining dialysis treatments — making the therapy manageable to a broad range of users across a wide range of environments, from the ICU to the home.

SC+ is CE Marked and commercially available in the UK, where it has been successfully used to treat patients across a range of care settings, from the ICU and the clinic to the home. The innovative and patented technology behind SC+ is based on a design breakthrough that allows all dialysate fluid management to be conducted on a small, lightweight, disposable cartridge. The unobtrusive, simple-to-use and digitally connected design of SC+ is intended to empower more patients to take control of their lives with selfcare and home dialysis. Meanwhile, as a portable, compact, and versatile device, SC+ provides flexibility to deliver across a wide range of use environments and prescriptions. SC+ is not yet FDA cleared and not yet available for sale in the USA

ALCESTER, England and BEVERLY, Massachusetts, 31 August 2021: Quanta Dialysis Technologies Ltd (“Quanta” or the “Company”), a medical technology leader delivering on its vision for more flexible and accessible dialysis care, announced today that John E. Milad, Chief Executive Officer, will present at the 2021 Wells Fargo Virtual Healthcare Conference on Friday, September 10, 2021, at 9:20 a.m. Eastern Time.

A live webcast of the presentation will be accessible through the following link: https://kvgo.com/wells-fargo/quanta-dialysis-technologies-sept-2021

12 February 2021: QUANTA Dialysis Technologies Ltd, a British medical technology pioneer developing innovative dialysis products and services for the global market, today announces the appointment of Dr Selwayan Saini as Chief Operating Officer with immediate effect.

Dr Saini brings with him over 15 years of experience working in senior operational roles in large global companies and in rapidly growing start-ups. Most recently he was Senior Director of Operations at Oxford Nanopore Technologies and prior to that he held various senior positions including CEO at Medtech Inside Biometrics and Vice President and Worldwide Director at Johnson & Johnson Medical Devices & Diagnostics. While at JNJ, he made significant contributions to chronic health management in the areas of diabetes care, which are now industry practice, such as removing the patient need to calibrate blood glucose meters and digital health connectivity (including work with Apple Inc.).

Dr Saini has an extensive track-record of developing and scaling successful medical technologies, with deep expertise in engineering, operations and manufacturing and in delivering best-in-class patient-centric solutions. Dr Saini obtained his PhD from Cranfield University, a British postgraduate research university specialising in science, engineering, technology and management.

John E Milad, CEO of QUANTA, said: “As we begin scaling-up our manufacturing and operational activities in the UK and US, Dr Saini’s experience of leading complex operations and driving continuous product improvement will be invaluable. I would like to welcome Dr Saini to QUANTA and look forward to working with him to bring the benefits of SC+ to as many patients and healthcare professionals as possible.”

Alcester, Warwickshire, UK, 8 January 2021: Quanta Dialysis Technologies Ltd (“Quanta” or “the Company”), a British medical technology pioneer developing innovative dialysis products and services for the global market, today announces it has received 510(k) clearance from the US Food and Drug Administration (“FDA”) to market its small and simple, high performance hemodialysis system SC+. This critical milestone enables Quanta to bring to the American market its portable device that can provide a dialysis dose equivalent to today’s standard of care, but in a compact, easy-to-use format suitable for a range of care settings.

The SC+ System in the US

There are more than half a million patients requiring hemodialysis in the United States. The vast majority of these patients receive dialysis three-times-a-week, with a minority receiving more frequent therapy. Unlike other portable hemodialysis systems, SC+ can deliver the higher dialysate flow rates typically used to provide conventional three-times-a-week prescriptions, while also offering the flexibility for more frequent, longer and gentler treatments tailored to patients’ needs. The small, lightweight design of SC+ makes the device portable, allowing for dialysis treatments to be brought to patients, and the simple, intuitive user interface makes dialysis accessible to a broad range of healthcare professionals.

In preparation for commercial launch, Quanta continues to develop its US team and operations. Following the appointment earlier this year of the Company’s President of North America, John Lipman, Quanta has also recently hired a Head of Chronic Sales and a Head of Clinical Support, while also building a dedicated US-based team that includes training, customer care and technical staff to support the Company’s customers and users.

To complement SC+, Quanta will introduce a suite of related products and services. This includes an optional, portable water purification module that will enable SC+ to be easily moved around and to be operated in a wide range of settings, both with and without a centralized water system, and a secure, cloud-based digital health offering that will simplify and automate treatment data capture and reporting, negating the need to create and store manual records.

Following extensive clinical piloting with the National Health Service (NHS) in England, SC+ became commercially available in the UK last year, playing a vital role in supporting the increased need for more simple, flexible dialysis devices in the hospital and the home, particularly during the rise of the COVID-19 pandemic. As reported in a recently published study (Komenda et al, Kidney Medicine 2020), SC+ combines the power and performance of larger conventional dialysis machines with the convenience of a compact, portable, user friendly device, making SC+ a much-needed addition to existing dialysis treatment options.

24 November 2020: Quanta Dialysis Technologies Ltd, a British medical technology company developing innovative dialysis products and services, announces the appointment of John S. Lipman as President of North America. John will lead Quanta’s commercial operations and activities in the United States. He is already working to set up operations and to prepare for commercial launch, which is planned to follow soon after 510(k) clearance is obtained from the FDA for the company’s portable haemodialysis system SC+. He is also joined by Deborah Singer and Michelle Gazella as Head of Chronic Sales and Head of Clinical Support, respectively, bringing more than 40 years’ sales and clinical dialysis experience, with both holding senior positions at Fresenius Medical Care and NxStage. John has over 25 years of leadership experience, developing and leading pre-launch and commercial companies across the medical device industry.

John began working with Quanta as a consultant, and before that was Chief Commercial Officer at NightBalance for four years prior to its acquisition by Philips, where he was responsible for leading the US launch of the Lunoa sleep therapy device. At ApniCure John was Vice President of Marketing & Sales for eight years, where he deployed and expanded a US sales team to launch a new treatment for Obstructive Sleep Apnea. John has also held positions at FoxHollow Technologies and two Johnson & Johnson subsidiaries, LifeScan and Scios. He graduated from California Polytechnical State University and holds an MBA in Marketing from the University of San Francisco.

Commenting on his appointment, John Lipman said, “I’m excited to be leading Quanta’s US business development and commercial activity at such an important time in the company’s development. SC+ represents a unique and disruptive opportunity for the US haemodialysis market, which rarely sees any innovation. In an industry which is notoriously slow to adapt and bring benefits from new technology to patients, Quanta is offering a versatile solution, designed with flexibility and freedom in mind that could revolutionise the way we think about kidney care. I look forward to leading Quanta’s US commercial operations and working together with the senior leadership team to bring SC+ to as many patients and healthcare professionals as we can.”

31 July, 2020: Quanta Dialysis Technologies Ltd, a British medical technology innovator, today announces that John E. Milad, Chief Executive Officer, will present a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners, on August 4 and 5, 2020.

Please click the following link to register: https://lifesci.events/SummerSymposium

Presentation Details

Date: August 5, 2020
Time: 11:00am Eastern Time

22 July 2020: Quanta Dialysis Technologies Ltd, a British medical technology innovation company, today announces the appointment of Hooman Hakami to the Company’s Board as an independent Non-Executive Director, with immediate effect.

Hooman has 30 years of leadership experience, including senior positions at two of the world’s largest medical devices companies. At Medtronic, he was Executive Vice President and President of the Diabetes Group and prior to that he spent more than 20 years at General Electric, where he was a Company Officer.

Johan de Ruiter, Chairman of the board said, “I am very pleased to welcome Hooman to the Quanta Board. His commercial experience in introducing disruptive technologies will be a large asset to the Company as we continue with the rollout and preparation of US market launch of SC+, Quanta’s small, simple and versatile haemodialysis system. I look forward to working with Hooman as we expand production of SC+ over the coming months, improving the lives of haemodialysis patients”.